SHC vs. PGNY, RDNT, AGL, QGEN, DVA, FMS, SGRY, IDYA, SMMT, and FOLD
Should you be buying Sotera Health stock or one of its competitors? The main competitors of Sotera Health include Progyny (PGNY), RadNet (RDNT), agilon health (AGL), Qiagen (QGEN), DaVita (DVA), Fresenius Medical Care (FMS), Surgery Partners (SGRY), IDEAYA Biosciences (IDYA), Summit Therapeutics (SMMT), and Amicus Therapeutics (FOLD). These companies are all part of the "medical" sector.
Sotera Health (NASDAQ:SHC) and Progyny (NASDAQ:PGNY) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, community ranking, media sentiment and analyst recommendations.
Progyny has a net margin of 5.53% compared to Sotera Health's net margin of 5.09%. Sotera Health's return on equity of 48.47% beat Progyny's return on equity.
In the previous week, Progyny had 41 more articles in the media than Sotera Health. MarketBeat recorded 43 mentions for Progyny and 2 mentions for Sotera Health. Sotera Health's average media sentiment score of 0.47 beat Progyny's score of 0.08 indicating that Sotera Health is being referred to more favorably in the media.
Progyny received 41 more outperform votes than Sotera Health when rated by MarketBeat users. Likewise, 74.78% of users gave Progyny an outperform vote while only 56.96% of users gave Sotera Health an outperform vote.
Progyny has higher revenue and earnings than Sotera Health. Progyny is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks.
91.0% of Sotera Health shares are held by institutional investors. Comparatively, 94.9% of Progyny shares are held by institutional investors. 55.1% of Sotera Health shares are held by company insiders. Comparatively, 12.3% of Progyny shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Sotera Health presently has a consensus price target of $17.70, indicating a potential upside of 55.13%. Progyny has a consensus price target of $44.11, indicating a potential upside of 60.11%. Given Progyny's stronger consensus rating and higher probable upside, analysts plainly believe Progyny is more favorable than Sotera Health.
Sotera Health has a beta of 2.08, meaning that its stock price is 108% more volatile than the S&P 500. Comparatively, Progyny has a beta of 1.51, meaning that its stock price is 51% more volatile than the S&P 500.
Summary
Progyny beats Sotera Health on 12 of the 18 factors compared between the two stocks.
Get Sotera Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for SHC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SHC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sotera Health Competitors List
Related Companies and Tools
